We've been anticipating this study for a looooooong time, but it's finally here.  It's probably good to review past OD Central posts about cross-linking, so here goes:

September 2011:  Avedro gets FDA approval for orphan drug status for CXL for KCN treatment.

December 2011:  Avedro gets FDA approval for orphan drug status for CXL for post-LASIK ectasia treatment.

January 2012:  Avedro gets European CE approval for LASIK Xtra, a procedure combining LASIK and CXL.

January 2012:  Avedro gets Canadian approval for LASIK Xtra.

March 2012:  Avedro submits New Drug Application to FDA.

April 2012:  Avedro announces it's newly-approved FDA study to compare CXL efficacy as a treatment for KCN.

June 2012:  Avedro is making improvements to its Riboflavin Ophthalmic Solution to allow for faster corneal penetration.  - jw